Systemic safety profile

Ind also explained that, since cidesonide is activated in the lung, it has an improved systemic safety profile compared with other corticosteroids, and patients should be less likely to suffer from local side effects. 

The traditional scheme is complicated by the fact that some antidepressants exhibit characteristics of more than one class. For example, clomipramine, a tricyclic antidepressant (TCA) with side effects and toxicity similar to other TCAs, works more like the selective serotonin reuptake inhibitors (SSRls). Similarly, venlafaxine and duloxetine, which are usually grouped with the atypical antidepressants, have a side effect and safety profile comparable to the SSRls. Although a classihcation system based on mechanism of action offers some advantage (see Table 3.7), even this scheme is limited by the fact that antidepressants that work in the same way may have widely divergent side effect and safety profiles. In the following discussion, the traditional classification system is adopted. Although fraught with problems and inconsistencies. 

Transcoronary venous injection is performed with a catheter system threaded percutaneously into the coronary sinus. Initial studies in swine have confirmed the feasibility and safety of this approach [121]. This delivery method has also been used to deliver skeletal myoblasts to scarred myocardium in cardiomyopathy patients [120]. With intravascular ultrasound guidance, this approach allows the operator to extend a catheter and needle away from the pericardial space and coronary artery into the adjacent myocardium. To date, human feasibility studies have had a good safety profile. This technique is limited, however, by coronary venous tortuosity, lack of site specific targeting, and its own technically challenging nature. Unlike the transendocardial approach, in which cells are... 

During the early twentieth century the barbiturates were used in children and adolescents for their sedative and hypnotic effects however, their safety profile and propensity to cause physical dependence led scientists in search of safer anxiolytics. The development of animal models of behavioral disorders facilitated the formulation of drugs with more specific central nervous system (CNS) effects. In 1959, chlordiazepoxide (Librium) was the first benzodiazepine (BZ) to receive a patent. It entered the market in 1960, followed by diazepam (Valium) in 1963. Today, over 35 BZs have been formulated and over 10 are available in the United States (Ballenger, 1995 Hobbs et ah, 1996). 

Fuel Oil/Bunker C CAS number Flash point IBP Safety profile 68553-00-4 180°F (82.2°C) 400°F (204°C) Vapors can cause respiratory system irritation and dizziness. Direct contact can be severely irritating to eyes and skin. 

Given the complexity that arises from the multitude of interacting variables associated with DPI systems, there are very few excipients that have been incorporated into DPI formulations. Examples of commonly marketed products are listed in Table 2. Lactose has many benefits including a well-established safety profile, low cost, and wide availability. Physicochemical properties of lactose are also relatively desirable from a DPI formulation standpoint smooth surfaces, crystalline, and moderate flow properties. However, lactose may not be suitable for some active... 

In general, ciclesonide in daily doses of up to 640 micrograms can be considered to be safe with respect to adrenal function. Its long-term safety profile is similarly advantageous, and administration in daily doses up to 1280 micrograms over 52 weeks was not associated with systemic or local adverse effects in patients with persistent asthma (50). 

One major concern regarding the safety profile of ME systems intended for oral administration is the comparatively high amphiphile content. Both o/w and w/o ME systems are amphiphile-rich systems compared to conventional emulsions and would contain in the most conservative case up to 15-20% w/w surfactant-cosurfactant. This is further complicated by the limited models available to evaluate chronic toxicology in comparison to conventional oral dosage forms such as tablets [91]. 

SAFETY PROFILE Poison by subcutaneous and intravenous routes. Moderately toxic by intraperitoneal route. Human systemic effects by ingestion dyspnea. An experimental teratogen by many routes. Other experimental reproductive effects. When heated to decomposition it emits ver toxic fumes of NOx and SOx. A carbonic anhydrase inhibitor and diuretic used to treat glaucoma. 

DOT CLASSIFICATION 8 Label Corrosive SAFETY PROFILE A human poison by an unspecified route. Moderately toxic by various routes. A severe eye and skin irritant. Can cause burns, lachrymation, and conjunctivitis. Human systemic effects by ingestion changes in the esophagus, ulceration, or bleeding from the small and large intestines. Human systemic irritant effects and mucous membrane irritant. Experimental reproductive effects. Mutation data reported. A common air contaminant. 

SAFETY PROFILE Moderately toxic by various routes. A skin and severe eye irritant. Human systemic effects by inhalation changes in EEG, changes in... 

---